BRPI0809047B8 - composição, aditivo alimentar e métodos para tratar ou prevenir diabetes ou obesidade e para reduzir o índice glicêmico de um alimento contendo carboidrato - Google Patents

composição, aditivo alimentar e métodos para tratar ou prevenir diabetes ou obesidade e para reduzir o índice glicêmico de um alimento contendo carboidrato

Info

Publication number
BRPI0809047B8
BRPI0809047B8 BRPI0809047A BRPI0809047A BRPI0809047B8 BR PI0809047 B8 BRPI0809047 B8 BR PI0809047B8 BR PI0809047 A BRPI0809047 A BR PI0809047A BR PI0809047 A BRPI0809047 A BR PI0809047A BR PI0809047 B8 BRPI0809047 B8 BR PI0809047B8
Authority
BR
Brazil
Prior art keywords
composition
obesity
carbohydrate
methods
food
Prior art date
Application number
BRPI0809047A
Other languages
English (en)
Portuguese (pt)
Inventor
Lee Thompson Daryl
Joseph Ahrens Milton
Original Assignee
Atm Metabolics Lllp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39590291&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0809047(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Atm Metabolics Lllp filed Critical Atm Metabolics Lllp
Publication of BRPI0809047A2 publication Critical patent/BRPI0809047A2/pt
Publication of BRPI0809047B1 publication Critical patent/BRPI0809047B1/pt
Publication of BRPI0809047B8 publication Critical patent/BRPI0809047B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0809047A 2007-03-19 2008-03-11 composição, aditivo alimentar e métodos para tratar ou prevenir diabetes ou obesidade e para reduzir o índice glicêmico de um alimento contendo carboidrato BRPI0809047B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89548607P 2007-03-19 2007-03-19
US60/895,486 2007-03-19
PCT/US2008/056474 WO2008115723A1 (en) 2007-03-19 2008-03-11 Composition for treating diabetes and metabolic disorders with quercetin, myrcetin and chlorogenic acid

Publications (3)

Publication Number Publication Date
BRPI0809047A2 BRPI0809047A2 (pt) 2014-09-02
BRPI0809047B1 BRPI0809047B1 (pt) 2020-09-01
BRPI0809047B8 true BRPI0809047B8 (pt) 2021-05-25

Family

ID=39590291

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0809047A BRPI0809047B8 (pt) 2007-03-19 2008-03-11 composição, aditivo alimentar e métodos para tratar ou prevenir diabetes ou obesidade e para reduzir o índice glicêmico de um alimento contendo carboidrato

Country Status (8)

Country Link
US (2) US7943164B2 (OSRAM)
EP (1) EP2129371B1 (OSRAM)
JP (1) JP2010522185A (OSRAM)
CN (1) CN101674821B (OSRAM)
BR (1) BRPI0809047B8 (OSRAM)
CA (1) CA2685031A1 (OSRAM)
MX (1) MX2009009996A (OSRAM)
WO (1) WO2008115723A1 (OSRAM)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7943164B2 (en) * 2007-03-19 2011-05-17 Milton Joseph Ahrens Composition and method for treating diabetes and metabolic disorders
JP5524466B2 (ja) * 2008-10-31 2014-06-18 ユニテックフーズ株式会社 中性風味デザートベース
US20100178413A1 (en) * 2008-12-17 2010-07-15 Mark Gorris Food-based Supplement Delivery System
US9918489B2 (en) * 2008-12-17 2018-03-20 Mark Gorris Food-based supplement delivery system
JP2011001311A (ja) * 2009-06-19 2011-01-06 Pola Chemical Industries Inc 熱産生タンパク質発現促進剤
EP2464243A1 (en) * 2009-08-10 2012-06-20 Stokely-Van Camp, Inc. Method for suspending a flavonoid in a beverage
US9693577B2 (en) 2010-01-29 2017-07-04 Abbott Laboratories Method of preparing a nutritional powder comprising spray dried HMB
SG182808A1 (en) 2010-01-29 2012-09-27 Abbott Lab Aseptically packaged nutritional liquids comprising hmb
RU2012125881A (ru) 2010-01-29 2014-03-10 Эбботт Лэборетриз Питательные эмульсии, содержащие бета-гидрокси-бета-метилбутират кальция (гмб кальция)
TWI526161B (zh) 2010-06-10 2016-03-21 亞培公司 包含鈣ｈｍｂ及可溶性蛋白質之實質上透明營養液
US8372447B2 (en) * 2010-08-03 2013-02-12 Northern Innovations And Formulations Corp. Compositions and methods for promoting weight loss and increasing energy
WO2012097064A1 (en) * 2011-01-13 2012-07-19 Abbott Laboratories Nutritional compositions and methods for controlling blood glucose
US20140065099A1 (en) 2011-02-15 2014-03-06 Ecole Polytechnique Federale De Lausanne (Epfl) Methods of Treating Mitochondrial Dysfunction
US9387219B2 (en) 2011-06-06 2016-07-12 Conopco, Inc. Edible composition
EP2726881A1 (en) 2011-06-28 2014-05-07 Koninklijke Philips N.V. Means for the examination of body fluids
CN102772424B (zh) * 2012-06-13 2014-01-08 浙江大学 新橙皮苷在制备防治糖尿病药物中的应用
KR101396059B1 (ko) * 2012-06-25 2014-05-16 중앙대학교 산학협력단 소귀나무잎으로부터 분리된 신규 황산염 페놀성 화합물 및 이의 항산화 및 항염 용도
CN104395751B (zh) 2012-06-29 2016-10-19 皇家飞利浦有限公司 含有干扰颗粒的流体的处理
CN104395736B (zh) 2012-06-29 2018-12-11 皇家飞利浦有限公司 对结合的磁性粒子和未结合的磁性粒子进行处理
US9823241B2 (en) 2012-07-18 2017-11-21 Koninklijke Philips N.V. Processing of a sample fluid with target components
WO2014083474A1 (en) 2012-11-30 2014-06-05 Koninklijke Philips N.V. Capture particle for selectively binding a target molecule
US11071767B2 (en) 2014-04-13 2021-07-27 Marmar Investment Sp. Z O.O. Dietary compositions for reducing blood glucose levels and for weight management
JP6639424B2 (ja) 2014-06-25 2020-02-05 コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． 試料内の標的成分を検出するバイオセンサ
US20170326194A1 (en) * 2014-12-01 2017-11-16 Cape Kingdom Nutraceuticals (Pty) Ltd Therapeutic compositions
US10690663B2 (en) 2015-03-26 2020-06-23 Koninklijke Philips N.V. Manufacturing of a biosensor cartridge
CN105816473B (zh) * 2015-07-06 2018-04-10 武汉华纳联合药业有限公司 一种黄酮苷类组合物及其制剂和制法
JP2017105745A (ja) * 2015-12-02 2017-06-15 共栄化学工業株式会社 皮膚外用剤
US20180133243A1 (en) * 2016-11-16 2018-05-17 Holista Colltech Ltd Method and composition for crude formulations of fortified sugar for glycemic control
TWI736755B (zh) 2017-04-03 2021-08-21 大江生醫股份有限公司 包含植物萃取物的組成物及其減少紫外線所致皮膚損傷之用途
WO2020247961A1 (en) * 2019-06-07 2020-12-10 Advanced Delivery Labs Llc Compositions and methods for improving wellness
CN111387504A (zh) * 2020-04-15 2020-07-10 武汉森澜生物科技有限公司 一种含绿原酸和柚皮苷的活性提取物、提取方法及其用途
WO2023192259A1 (en) * 2022-03-28 2023-10-05 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synergy for increasing insulin sensitivity

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3134233B2 (ja) * 1991-07-26 2001-02-13 株式会社林原生物化学研究所 α−グリコシル ケルセチンとその製造方法並びに用途
ATE275834T1 (de) * 1997-03-20 2004-10-15 Coventry Group Ltd Nährungsergänzungsmittel für kardiovasküläre gesundheit
US7229651B2 (en) * 1997-08-06 2007-06-12 Melaleuca, Inc. Dietary supplements containing natural ingredients
KR20000019716A (ko) * 1998-09-15 2000-04-15 박호군 바이오플라보노이드 화합물을 포함하는 혈당 강하용 조성물
US20020068704A1 (en) * 1999-04-05 2002-06-06 Ziegler Randy H. Compositions and methods for treatment of diabetes
AU2001251610A1 (en) * 2000-04-13 2001-11-07 Ocean Spray Cranberries, Inc. Novel compositions derived from cranberry and grapefruit and therapeutic uses therefor
US20030108627A1 (en) * 2001-09-25 2003-06-12 Jonathan Selzer Cranberry based dietary supplement and dental hygiene product
US20030133945A1 (en) * 2002-01-11 2003-07-17 Farley Michael Donald Natural food supplement
WO2004041265A1 (ja) * 2002-11-06 2004-05-21 Kao Corporation 血液流動性改善剤
US7270837B2 (en) * 2003-11-10 2007-09-18 Rutgers, The State University Of New Jersey Anti-inflammatory cranberry flavonol extract preparations
US8017634B2 (en) * 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
WO2006024545A1 (en) 2004-09-03 2006-03-09 Stichting Voor De Technische Wetenschappen Fused bicyclic natural compounds and their use as inhibitors of parp and parp-mediated inflammatory processes
US20060188590A1 (en) * 2005-01-05 2006-08-24 Mitsunori Ono Compositions for treating diabetes or obesity
US20070092454A1 (en) * 2005-10-24 2007-04-26 Colgate-Palmolive Company Oral composition containing morin
US7943164B2 (en) * 2007-03-19 2011-05-17 Milton Joseph Ahrens Composition and method for treating diabetes and metabolic disorders

Also Published As

Publication number Publication date
CA2685031A1 (en) 2008-09-25
EP2129371A1 (en) 2009-12-09
CN101674821A (zh) 2010-03-17
JP2010522185A (ja) 2010-07-01
US8198319B2 (en) 2012-06-12
MX2009009996A (es) 2010-01-20
US20080234364A1 (en) 2008-09-25
US7943164B2 (en) 2011-05-17
US20110118345A1 (en) 2011-05-19
BRPI0809047A2 (pt) 2014-09-02
EP2129371B1 (en) 2021-05-05
BRPI0809047B1 (pt) 2020-09-01
WO2008115723A1 (en) 2008-09-25
CN101674821B (zh) 2013-06-26

Similar Documents

Publication Publication Date Title
BRPI0809047B8 (pt) composição, aditivo alimentar e métodos para tratar ou prevenir diabetes ou obesidade e para reduzir o índice glicêmico de um alimento contendo carboidrato
EA200801897A1 (ru) Ингибиторы mnk2 на основе 8-гетероарилпурина для лечения метаболических нарушений
EP2217596B8 (en) Bicyclic heterocycle derivatives and their use as modulators of the activity of gpr119
BR112013011249A2 (pt) inibidores de ibat para tratamento de distúrbios metabólicos e condições relacionadas
CR10402A (es) Inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1
DOP2007000078A (es) Derivados de ciclohexilpirazol-lactama como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1
BR112012031873A2 (pt) antagonistas de ciclo-hexil-azetidinila do ccr2
MY158994A (en) Ampk modulators
IL195030A (en) Dpp iv inhibitor formulations
BR112015014420A2 (pt) oligossacarídeos do leite humano para melhorar sintomas de estresse
MX2015008114A (es) Derivados de exendina-4.
MX352412B (es) Tratamiento de enfermedades relacionadas con eritropoyetina (epo) mediante inhibicion del transcrito antisentido natural a eritropoyetina.
WO2008120713A1 (ja) 副交感神経活動亢進作用を有する医薬組成物又は飲食物
EP3489360A3 (en) Modulation of nuclear-retained rna
EA201201648A1 (ru) Стимуляторы sgc
EP3318262A3 (en) Composition for preventing or treating bone disease, obesity and lipid-related metabolic disease
ECSP13012661A (es) Composición farmacéutica, métodos de tratamiento y usos de la misma.
MA33974B1 (fr) Combinaisons d'un inhibiteur de pi3k et d'un inhibiteur de mek
BR112012031103A2 (pt) método para tratar um paciente sofrendo de um distúrbio metabólico, método para tratar pelo menos um desarranjo não-metabólico em um paciente, método para tratar pelo menos em desarranjo metabólico e pelo menos em desarranjo não-metabólico em um paciente, método para tratar pelo menos uma doença vascular em um paciente e composição farmacêutica efetiva para tratar a síndrome metabólica, diabetes tipo 2, obesidade, ou pré-diabetes
BRPI0914907A8 (pt) Composição particulada para ração e ração
MX349254B (es) Compuestos para el tratamiento del sindrome metabolico.
BR112012008599A2 (pt) composto da formula (i), composto da fórmula (ia), composto da fórmula (ic), composto da fórmula (ii), composto da fórmula (iia), composto, método para tratamento de um transtorno hiperproliferativo em um mamífero, que inclui um humano, método para tratamento de uma doença, condição ou transtorno inflamatório em um mamífero, que inclui um humano, método para tratamento de um transtorno ou condição que é modulada pela cascata de meik em um mamífero, que inclui um himano, método para tratar ou prevenir câncer, composição farmacêutica e método para inibir uma enzima mek
MX2020006720A (es) Beta-caseina a2 y niveles de glucosa en sangre.
EA201591943A1 (ru) Ингибиторы metap2 и способы лечения ожирения
BRPI0811881A8 (pt) Condimento, alimento ou bebida, composição, e método para melhorar o sabor de um sal de potássio

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 31/353 (2006.01), A23L 33/105 (2016.01), A61K

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 01/09/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/03/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2765 DE 02-01-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.